Department of Internal Medicine, Erasmus University Medical Center, PO Box 2040-Na27-24, 3000 CA, Rotterdam, The Netherlands.
Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Curr Osteoporos Rep. 2021 Feb;19(1):50-57. doi: 10.1007/s11914-020-00646-8. Epub 2021 Jan 12.
The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk in individuals with diabetes mellitus.
Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals with T2DM. Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.
本文旨在总结近期发表的有关糖尿病患者椎体骨折风险的证据。
2 型糖尿病患者的椎体骨折风险增加。2 型糖尿病患者存在椎体骨折与非椎体骨折风险增加和死亡率升高相关。骨密度 T 值可有助于评估 2 型糖尿病患者的椎体骨折风险。2 型糖尿病患者的骨髓脂肪含量增加与骨脆性相关。最近两项研究的结果表明,特立帕肽和地舒单抗均可有效降低 2 型糖尿病患者的椎体骨折风险。2 型糖尿病患者可从临床椎体骨折筛查中获益。